<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473316</url>
  </required_header>
  <id_info>
    <org_study_id>GP27913</org_study_id>
    <nct_id>NCT01473316</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980</brief_title>
  <official_title>An Open-Label, Fixed-Sequence, 2-Period Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This will be an open-label, fixed-sequence, single-center, 2 period study. The study is&#xD;
      designed to determine the effect of ketoconazole on the pharmacokinetics of GDC-0980.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: maximum observed plasma concentration</measure>
    <time_frame>Up to approximately 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: time to reach maximum observed plasma concentration</measure>
    <time_frame>Up to approximately 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to approximately 40 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory test results (hematology and serum chemistry)</measure>
    <time_frame>Up to approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital sign measurements (sitting systolic and diastolic blood pressure, heart rate, respiratory rate, and temperature)</measure>
    <time_frame>Up to approximately 8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0980</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>Repeating Oral Dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy postmenopausal and/or surgically sterile adult nonsmoking female subject&#xD;
             between 18 and 65 years of age, inclusive, with a body mass index of 18 to 32 kg/m2,&#xD;
             inclusive&#xD;
&#xD;
          -  Medically healthy as determined by the absence of clinically significant findings in&#xD;
             the physical examination, medical history, vital sign measurements, clinical&#xD;
             laboratory tests, or 12 lead electrocardiograms (ECGs) as determined by the&#xD;
             investigator&#xD;
&#xD;
          -  Female subject of nonchildbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or clinical manifestations of significant metabolic (including type 1 and 2&#xD;
             diabetes), hepatic, renal, hematological (including hypercholesterolemia and&#xD;
             triglyceridemia), pulmonary, cardiovascular, endocrine, gastrointestinal (including&#xD;
             gastric or duodenal ulcers), urological, neurological, or psychiatric disorders, or&#xD;
             cancer&#xD;
&#xD;
          -  History of inflammatory arthritis&#xD;
&#xD;
          -  History of symptomatic hypotension&#xD;
&#xD;
          -  History of severe physical injury, direct impact trauma, or neurological trauma within&#xD;
             6 months before Day 1 of Period 1&#xD;
&#xD;
          -  History of seizure disorders&#xD;
&#xD;
          -  History of bipolar or major depressive disorder&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection that could potentially alter&#xD;
             absorption and/or excretion of orally administered drugs, with the exception of&#xD;
             appendectomy, hernia repair, and cholecystectomy, which are allowed&#xD;
&#xD;
          -  History of active liver disease, including hepatitis or cirrhosis&#xD;
&#xD;
          -  History or presence of an abnormal ECG&#xD;
&#xD;
          -  History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias&#xD;
&#xD;
          -  Abnormality on the chest x-ray at Screening determined to be clinically significant by&#xD;
             the investigator and medical monitor&#xD;
&#xD;
          -  History of alcoholism, drug abuse, or drug addiction&#xD;
&#xD;
          -  Used any nicotine-containing or nicotine-replacement products within 6 months before&#xD;
             Day 1 of Period 1&#xD;
&#xD;
          -  Participated in any other investigational drug study in which receipt of an&#xD;
             investigational study drug occurred within 1 month or 5 half-lives before Day 1 of&#xD;
             Period 1&#xD;
&#xD;
          -  Used any prescription medications/products including monoamine oxidase inhibitors,&#xD;
             thioridazine, pimozide, or antidepressants within 1 month (2 weeks for antibiotics)&#xD;
             before Day 1 of Period 1, with the exception of hormone replacement therapy or 2&#xD;
             weeks' use of narcotics for pain, unless deemed acceptable by the investigator&#xD;
&#xD;
          -  Used medications capable of inhibiting hepatic enzymes within 1 month or 5 half-lives&#xD;
             before Day 1 of Period 1&#xD;
&#xD;
          -  Received any vaccination or immunization within 1 month before Day 1 of Period 1&#xD;
&#xD;
          -  Used proton pump inhibitors or histamine H2 receptor antagonists within 1 month before&#xD;
             Day 1 of Period 1&#xD;
&#xD;
          -  Known hypersensitivity to ketoconazole, or other azole antifungals&#xD;
&#xD;
          -  Used any over-the-counter, nonprescription preparations within 7 days before Day 1 of&#xD;
             Period 1, unless deemed acceptable by the investigator&#xD;
&#xD;
          -  Used alcohol-containing, grapefruit-containing, or caffeine containing foods or&#xD;
             beverages within 72 hours before Day 1 of Period 1, unless deemed acceptable by the&#xD;
             investigator&#xD;
&#xD;
          -  Poor peripheral venous access&#xD;
&#xD;
          -  Donated blood within 2 weeks or plasma within 1 week before Day 1 of Period 1&#xD;
&#xD;
          -  Received blood products within 2 months before Day 1 of Period 1&#xD;
&#xD;
          -  Positive urine drug or alcohol screen&#xD;
&#xD;
          -  Positive screen for hepatitis B surface antigen, hepatitis C virus, or human&#xD;
             immunodeficiency virus types 1 and 2&#xD;
&#xD;
          -  Diagnosed with a vitamin B12 deficiency&#xD;
&#xD;
          -  Any acute or chronic condition that, in the opinion of the investigator, would limit&#xD;
             the subject's ability to complete or participate in this clinical study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 10, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

